Company Overview: Capricor Therapeutics

Industry News

21 Jan

Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET

Presentation to Discuss Capricor’s Duchenne Muscular Dystrophy Clinical Program LOS ANGELES, Jan. 21, 2015 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases and CureDuchenne, a national nonprofit organization dedicated to finding a cure for Duchenne muscular...

Read more

12 Jan

Cure Duchenne Ventures LLC To Provide $1 Million to Capricor Therapeutics to Advance Promising Research to Treat Heart Disease Associated with Duchenne Muscular Dystrophy

NEWPORT BEACH, Calif.–(BUSINESS WIRE)— CureDuchenne Ventures LLC, a company that funds research to find a cure for Duchenne muscular dystrophy that was formed by the nonprofit CureDuchenne, announced today that they are investing $1 million in Capricor Therapeutics, a biotechnology company focused on developing novel therapeutics for the treatment...

Read more

12 Jan

Capricor Therapeutics Announces $10 Million Private Placement of Common Stock

Investors Include: Cedars-Sinai Medical Center, CureDuchenne Ventures LLC, Select Board Members and Capricor Management LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has signed definitive agreements for...

Read more

12 Jan

Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray’s 26th Annual Healthcare Conference

LOS ANGELES, Dec. 2, 2014 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that CEO and President Linda Marban will deliver an overview of Capricor Therapeutics, Inc., to Piper Jaffray’s clients during a fireside...

Read more

2 Dec

Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray’s 26th Annual Healthcare Conference

Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that CEO and President Linda Marban will deliver an overview of Capricor Therapeutics, Inc., to Piper Jaffray’s clients during a fireside chat session in the Rutherford Room of the...

Read more

18 Nov

Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy

Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced positive data from the laboratory of Eduardo Marbán, M.D., Ph.D., Capricor’s Scientific Advisory Board Chairman and the Director of the Cedars-Sinai Heart Institute. The abstract was presented at the Late...

Read more

18 Nov

Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results

Preliminary Efficacy Data Shows Encouraging Results- Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced yesterday at the American Heart Association’s Annual Scientific Sessions 2014, the one-year results of the Phase IALLSTAR (Allogeneic Heart Stem Cells to Achieve Myocardial...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address